Summer Street likes Afrezza's chances of passing regulatory muster as the firm says MannKind's...


Summer Street likes Afrezza's chances of passing regulatory muster as the firm says MannKind's (MNKD -3.4%) drug has "an 85 percent chance [of meeting] endpoint benchmarks of non-inferiority to injectable insulin." The analyst does cite some risks which could show up in trial results including hypoglycemia and cardiovascular problems.

From other sites
Comments (5)
  • Mark Moore
    , contributor
    Comments (22) | Send Message
     
    I sure hope it does because I have put everything I've got into it.
    21 Jun 2013, 11:44 AM Reply Like
  • svelas100
    , contributor
    Comment (1) | Send Message
     
    Al is the man and I'm betting a lot on this jockey myself
    21 Jun 2013, 12:32 PM Reply Like
  • lambchop3
    , contributor
    Comment (1) | Send Message
     
    An occasional episode of Hypoglycemia occurs with any fast-acting insulin. Hopefully, the cardiovascular risks will be negligible.
    21 Jun 2013, 12:32 PM Reply Like
  • Chemist357
    , contributor
    Comments (256) | Send Message
     
    can you quote an article with the hypoglycemia...Cause I have not seen it thru the clincal trials that I have seen that has been stat sig.

     

    Without linked article...you don't know what you are talking about!
    21 Jun 2013, 04:05 PM Reply Like
  • Pharma Guru
    , contributor
    Comments (11) | Send Message
     
    This product will change diabetes treatment protocols. It's Al Mann's crowning achievement and will become his legacy.
    14 Aug 2013, 05:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs